The loss of Arrowhead Pharmaceuticals under GAAP for the 3 months of fiscal year 2021 was $20.732 million, up 7.6 times from $2.673 million in the previous year. Revenue decreased 27.7% to $21.303 million from $29.455 million a year earlier.